Cargando…
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
Systemic autoimmune disorders are complex heterogeneous chronic diseases involving many different immune cells. A significant proportion of patients respond poorly to therapy. In addition, the high burden of adverse effects caused by “classical” anti-rheumatic or immune modulatory drugs provides a n...
Autores principales: | Neys, Stefan F. H., Rip, Jasper, Hendriks, Rudi W., Corneth, Odilia B. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491186/ https://www.ncbi.nlm.nih.gov/pubmed/34609725 http://dx.doi.org/10.1007/s40265-021-01592-0 |
Ejemplares similares
-
Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
por: Neys, Stefan F. H., et al.
Publicado: (2021) -
Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B‐cell receptor signaling in mice
por: Rip, Jasper, et al.
Publicado: (2021) -
Evidence for enhanced Bruton’s tyrosine kinase activity in transitional and naïve B cells of patients with granulomatosis with polyangiitis
por: von Borstel, Anouk, et al.
Publicado: (2019) -
Aberrant B Cell Signaling in Autoimmune Diseases
por: Corneth, Odilia B. J., et al.
Publicado: (2022) -
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
por: Geladaris, Anastasia, et al.
Publicado: (2022)